Jiaolong capsule protects SD rats against 2,4,6-trinitrobenzene sulfonic acid induced colitis

J Ethnopharmacol. 2021 Apr 6:269:113716. doi: 10.1016/j.jep.2020.113716. Epub 2021 Jan 18.

Abstract

Ethnopharmacological relevance: Jiaolong capsule (JLC) was approved for the therapy of gastrointestinal diseases by the State Food and Drug Administration (SFDA) of China. It has a satisfactory curative effect in the treatment of patients with inflammatory bowel disease, however, the mechanism remains to be elucidated.

Aim of the study: In current study, the effects and possible mechanisms of JLC on 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis were investigated.

Materials and methods: Sulfasalazine and JLC were administrated orally and initialized 6 h after TNBS enema, once a day for seven consecutive days. The effect of JLC on intestinal microbial populations and LPS/TLR-4/NF-κB pathway was observed and assessed. Thirty female SD rats were distributed into six groups randomly and equally, namely, control, TNBS, TNBS + sulfasalazine (625 mg/kg), and TNBS + three different doses of JLC (25, 50, and 100 mg/kg) groups.

Results: The effect of JLC on restoring normal structures of colorectum and repairing colonic damage were superior to that of sulfasalazine. JLC showed a positive effect in re-balancing intestinal bacteria population of colitis, and suppressed the activation of LPS/TLR-4/NF-κB pathway.

Conclusion: The results suggest that JLC demonstrated a beneficial effect on treating colitis in a rat model. The possible mechanisms may be through the regulatory effect of intestinal commensal bacteria and down-regulation of LPS/TLR-4/NF-κB pathway.

Keywords: Colitis; Jiaolong capsule; Toll like receptor 4.

MeSH terms

  • Acetic Acid / toxicity
  • Animals
  • Behavior, Animal / drug effects
  • Colitis, Ulcerative / chemically induced
  • Colitis, Ulcerative / drug therapy*
  • Colon / drug effects
  • Colon / pathology
  • Cyclooxygenase 2 / genetics
  • Cyclooxygenase 2 / metabolism
  • Dinoprostone / metabolism
  • Disease Models, Animal
  • Down-Regulation / drug effects
  • Drugs, Chinese Herbal / chemistry
  • Drugs, Chinese Herbal / pharmacology*
  • Drugs, Chinese Herbal / therapeutic use
  • Female
  • Gastrointestinal Agents / pharmacology*
  • Gastrointestinal Agents / therapeutic use
  • Gastrointestinal Microbiome / drug effects
  • Mice
  • Mice, Inbred ICR
  • NF-KappaB Inhibitor alpha / genetics
  • NF-KappaB Inhibitor alpha / metabolism
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Pain / chemically induced
  • Pain / drug therapy
  • Protective Agents / chemistry
  • Protective Agents / pharmacology*
  • Protective Agents / therapeutic use
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction / drug effects
  • Sulfasalazine / pharmacology
  • Sulfasalazine / therapeutic use
  • Toll-Like Receptor 4 / biosynthesis
  • Toll-Like Receptor 4 / drug effects
  • Transcription Factor RelA / genetics
  • Transcription Factor RelA / metabolism
  • Trinitrobenzenesulfonic Acid / toxicity

Substances

  • Drugs, Chinese Herbal
  • Gastrointestinal Agents
  • NF-kappa B
  • Protective Agents
  • Rela protein, rat
  • Tlr4 protein, rat
  • Toll-Like Receptor 4
  • Transcription Factor RelA
  • NF-KappaB Inhibitor alpha
  • Sulfasalazine
  • Trinitrobenzenesulfonic Acid
  • Cyclooxygenase 2
  • Ptgs2 protein, rat
  • Dinoprostone
  • Acetic Acid